2025-08-29 01:00:36
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Dr. Reddy's Laboratories Ltd Q4 FY20 consolidated PAT jumps to Rs. 764.2 crore
Posted On : 2020-05-20 15:44:07( TIMEZONE : IST )
DR.REDDY's LABORATORIES LTD. has reported financial results for the period ended March 31, 2020.
Financial Results (Q4 FY19-20) - QoQ Comparison
The company has reported total income of Rs.4522.5 crores during the period ended March 31, 2020 as compared to Rs.4464.4 crores during the period ended December 31, 2019.
The company has posted net profit / (loss) of Rs.764.2 crores for the period ended March 31, 2020 as against net profit / (loss) of Rs.(569.7) crores for the period ended December 31, 2019.
The company has reported EPS of Rs.47.03 for the period ended March 31, 2020 as compared to Rs.(32.48) for the period ended December 31, 2019.
| Financials | Q4 FY19-20 | Q3 FY19-20 | % Change |
| Total Income | ₹ 4522.5 crs | ₹ 4464.4 crs |  1.3% |
| Net Profit | ₹ 764.2 crs | ₹ (569.7) crs | 234.14% |
| EPS | ₹ 47.03 | ₹ (32.48) | 244.8% |
Financial Results (Q4 FY19-20) - YoY Comparison
The company has reported total income of Rs.4522.5 crores during the period ended March 31, 2020 as compared to Rs.4112.9 crores during the period ended March 31, 2019.
The company has posted net profit / (loss) of Rs.764.2 crores for the period ended March 31, 2020 as against net profit / (loss) of Rs.434.4 crores for the period ended March 31, 2019.
The company has reported EPS of Rs.47.03 for the period ended March 31, 2020 as compared to Rs.27.41 for the period ended March 31, 2019.
| Financials | Q4 FY19-20 | Q4 FY18-19 | % Change |
| Total Income | ₹ 4522.5 crs | ₹ 4112.9 crs | 9.96% |
| Net Profit | ₹ 764.2 crs | ₹ 434.4 crs | 75.92% |
| EPS | ₹ 47.03 | ₹ 27.41 | 71.58% |
Financial Results (12 months ended FY 19-20) - YoY Comparison
The company has reported total income of Rs.18137.6 crores during the 12 months period ended March 31, 2020 as compared to Rs.15785.7 crores during the 12 months period ended March 31, 2019.
The company has posted net profit / (loss) of Rs.1949.8 crores for the 12 months period ended March 31, 2020 as against net profit / (loss) of Rs.1879.5 crores for the 12 months period ended March 31, 2019.
The company has reported EPS of Rs.121.99 for the 12 months period ended March 31, 2020 as compared to Rs.117.33 for the 12 months period ended March 31, 2019.
| Financials | Year Ended FY19-20 | Year Ended FY18-19 | % Change |
| Total Income | ₹ 18137.6 crs | ₹ 15785.7 crs | 14.9% |
| Net Profit | ₹ 1949.8 crs | ₹ 1879.5 crs | 3.74% |
| EPS | ₹ 121.99 | ₹117.33 | 3.97% |
Commenting on the results, Co-Chairman and MD, GV Prasad said "FY 20 has been a very positive year for the company. Progress made during the year includes VAi status for CTO 6, healthy product pipeline build up, productivity improvement, and strong financial performance across our businesses".
Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.3710.2 as compared to the previous close of Rs. 3677.6. The total number of shares traded during the day was 20181 in over 2480 trades.
The stock hit an intraday high of Rs. 3723.6 and intraday low of 3663.15. The net turnover during the day was Rs. 74615956.
